Vision care is no longer limited to correcting eyesight; it’s becoming more innovative, more personalized, and increasingly integrated with advanced technologies. As the global market evolves, breakthroughs in diagnostics, treatment, and eyewear customization are driving innovation and making eye care more accessible and effective than ever before.
From AI-powered screenings to smart contact lenses, the vision care industry is undergoing a significant transformation. And it’s not just about innovation, it’s about impact. The market is expanding its reach across geographies and age groups, addressing everything from childhood myopia to age-related vision decline, while blending comfort, style, and performance into daily wear solutions.
According to BCC Research, the global market for vision care is expected to grow from $75.1 billion in 2025 to $98 billion by the end of 2030, at a compound annual growth rate (CAGR) of 5.5% during the forecast period from 2025 to 2030.
One of the most significant shifts in the vision care landscape is the increasing role of innovative diagnostic and treatment tools. Take, for instance, CooperVision’s MiSight 1-day contact lens, which has been explicitly FDA-approved for myopia control in children. Over the course of three years, it has been shown to reduce myopia progression by 59%, making it a game-changer in preventing long-term vision complications.
In India, Lenskart has introduced AI-powered kiosks that recommend frames and lenses based on a person’s facial features, combining convenience with personalized experiences. Meanwhile, EssilorLuxottica’s Eye-Ruler 2 uses facial recognition and 3D mapping to customize lenses in seconds, providing a futuristic approach to optical retail.
Even vision treatment is getting a tech boost. Zeiss’ VISULAS green laser now integrates with digital workflow systems, enhancing precision and efficiency in retinal procedures. And innovations like PlenOptika’s QuickSee, a portable and user-friendly autorefractor, have enabled vision screening for over 5 million people globally, particularly in underserved regions.
Corrective vision solutions are also witnessing breakthroughs. Alcon’s Vivity IOL, for example, features a non-diffractive intraocular lens design that enhances vision across multiple distances while reducing common side effects such as halos or glare. It’s part of a growing trend toward premium eye surgery outcomes and improved quality of life for aging populations.
Additionally, advancements in AI-powered diagnostic tools, such as EyeArt and IDx-DR, both FDA-cleared, are revolutionizing diabetic retinopathy detection in primary care settings. These tools can autonomously screen patients, improving access to vision care where specialist availability is limited.